[1]Fujita PA,Rhead B, Zweig AS, et al. The UCSC Genome Browser database: update 2011\[J\]. Nucleic Acids Research, 2011, 39(Database issue): D876-882.[2]Hurst DR, Edmonds MD, Welch DR. Metastamir: the field of metastasisregulatory microRNA is spreading\[J\]. Cancer Res, 2009, 69(19): 7495-7498.[3]Chou CK,Yang KD,Chou FF,et al.Prognostic implications of miR146b expression and its functional role in papillary thyroid carcinoma\[J\]. J Clin Endocrinol Metab, 2013, 98(2): E196-E205.[4]Chou CK,Chen Rf,Chou FF,et al.miR146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation\[J\]. Thyroid, 2010, 20(5): 489-494.[5]Hardin H, Guo Z, Shan W, et al. The roles of the epithelialmesenchymal transition marker PRRX1 and miR146b5p in papillary thyroid carcinoma progression\[J\]. Am J Pathol, 2014, 184(8): 2342-2354.[6]Geraldo MV, Yamashita AS, Kimura ET. MicroRNA miR146b5p regulates signal transduction of TGFβ by repressing SMAD4 in thyroid cancer\[J\]. Oncogene, 2012, 31(15): 1910-1922.[7]Landriscina M,Pannone G,Piscazzi A,et al.Epidermal growth factor receptor 1 expression is upregulated in undifferentiated thyroid carcinomas in humans\[J\]. Thyroid, 2011, 21(11):1227-1234.[8]Huang CJ, Jap TS.A systematic review of genetic studies of thyroid disorders in Taiwan\[J\]. J Chin Med Assoc, 2015, 78(3): 145-153.[9]Elsarraj HS,Hong Y,Valdez K, et al. A novel role of microRNA146b in promoting mammary alveolar progenitor cell maintenance\[J\]. J Cell Sci, 2013, 126(11): 2446-2458.[10]Garcia AI, Buisson M,Damiola F, et al. Mutation screening of MIR146A/B and BRCA1/2 3′UTRs in the GENESIS study\[J\]. Eur J Hum Genet, 2016, 24(9): 1324-1329.[11]Garcia AI, Buisson M, Bertrand P, et al. Downregulation of BRCA1 expression by miR146a and miR146b5p in triple negative sporadic breast cancers\[J\]. EMBO Mol Med, 2011, 3(5): 279-290.[12]Hurst DR, Edmonds MD,Scott GK,et al.Breast cancer metastasis suppressor 1 upregulates miR146, which suppresses breast cancer metastasis\[J\]. Cancer Res, 2009, 69(4): 1279-1283.[13]Walter BA, Valera VA, Pinto PA, et al. Comprehensive microRNA profiling of prostate cancer\[J\]. J Cancer, 2013, 4(5): 350-357.[14]Ding HY, Qian WQ, Xu J. MicroRNA146b acts as a potential tumor suppressor in human prostate cancer\[J\]. J BUON, 2016, 21(2): 434-443.[15]Wu PY,Zhang XD,Zhu J,et al. Low expression of microRNA146b5p and microRNA320d predicts poor outcome of large Bcell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone\[J\]. Hum Pathol, 2014, 45(8): 1664-1673.[16]Andrade TA, Evangelista AF, Campos AH,et al. A microRNA signature profile in EBV+ diffuse large Bcell lymphoma of the elderly\[J\]. Oncotarget, 2014, 5(23): 11813-11826.[17]Yang W, Yu H,Shen Y, et al. miR146b5p overexpression attenuates stemness and radioresistance of glioma stem cells by targeting HuR/lincRNAp21/βcatenin pathway\[J\]. Oncotarget,2016,7(27): 41505-41526.[18]Liu J,Xu J,Li H, et al. miR146b5p functions as a tumor suppressor by targeting TRAF6 and predicts the prognosis of human gliomas\[J\]. Oncotarget, 2015, 6(30): 29129-29142.[19]Li Y,Wang Y,Yu L,et al.MiR146b5p inhibits glioma migration and invasion by targeting MMP16\[J\]. Cancer Lett, 2013, 339(2): 260-269.[20]Katakowski M, Zheng X, Jiang F, et al. miR146b5p suppresses EGFR expression and reduces in vitro migration and invasion of glioma\[J\]. Cancer Invest,2010, 28(10): 1024-1030.[21]陈晓, 魏立, 陈重,等. miR146b5p通过抑制ATR通路诱导肺癌A594细胞凋亡\[J\].现代肿瘤医学, 2017, 25(20):3238-3241.[22]Patnaik SK,Kannisto E,Mallick R, et al. Overexpression of the lung cancerprognostic miR146b microRNAs has a minimal and negative effect on the malignant phenotype of A549 lung cancer cells\[J\]. PLoS One,2011, 6(7): e22379.[23]Taganov KD, Boldin MP, Chang KJ, et al. NFκBdependent induction of microRNA miR146, an inhibitor targeted to signaling proteins of innate immune responses\[J\]. Proc Natl Acad Sci U S A,2006, 103(33): 12481-12486.[24]Boldin MP,Taganov KD,Rao DS,et al.miR146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice\[J\]. J Exp Med, 2011, 208(6): 1189-1201.[25]Samuels TL, Yan J, Khampang P, et al. Association of microRNA 146 with middle ear hyperplasia in pediatric otitis media\[J\]. Int J Pediatr Otorhinolaryngol, 2016, 88: 104-108.[26]Pfeiffer D, Roβmanith E, Lang I, et al. miR146a, miR146b, and miR155 increase expression of IL6 and IL8 and support HSP10 in an in vitro sepsis model\[J\]. PLoS One, 2017, 12(6) :e0179850.[27]Wang D,Li T,Cui H,et al.Analysis of the indicating value of cardiac troponin I, tumor necrosis factorα,interleukin18,miR1 and miR146b for viral myocarditis among children\[J\].Cell Physiol Biochem, 2016, 40(6): 1325-1333.[28]Kutty RK,Nagineni CN,Samuel W,et al. Differential regulation of microRNA146a and microRNA146b5p in human retinal pigment epithelial cells by interleukin1β, tumor necrosis factorα, and interferonγ\[J\]. Mol Vis, 2013, 19: 737-750.[29]Xiang M, Birkbak NJ, Vafaizadeh V, et al. STAT3 induction of miR146b forms a feedback loop to inhibit the NFκB to IL6 signaling axis and STAT3driven cancer phenotypes\[J\]. Sci Signal, 2014, 7(310): ra11.[30]Etikala DM, Liu R, Wang L. FOXP3microRNA146NFκB as oncotarget\[J\]. Oncoscience, 2015, 2(10): 839-840.[31]Liu R, Liu C, Chen D, et al. FOXP3 controls an miR146/NFκB negative feedback loop that inhibits apoptosis in breast cancer cells\[J\]. Cancer Res, 2015, 75(8): 1703-1713.[32]Liu R,Yi B, Wei S, et al. FOXP3microRNA146NFκB axis and therapy for precancerous lesions in prostate\[J\]. Cancer Res, 2015, 75(8): 1714-1724.[33]Xu E,Zhao J,Ma J,et al.miR146b5p promotes invasion and metastasis contributing to chemoresistance in osteosarcoma by targeting zinc and ring finger 3\[J\]. Oncol Rep, 2016, 35(1): 275-283.[34]Echavarria R, Mayaki D, Neel JC, et al. Angiopoietin1 inhibits tolllike receptor 4 signalling in cultured endothelial cells: role of miR146b5p\[J\]. Cardiovasc Res, 2015, 106(3): 465-477.[35]Chang TY, Tsai WC, Huang TS, et al. Dysregulation of endothelial colonyforming cell function by a negative feedback loop of circulating miR146a and 146b in cardiovascular disease patients\[J\]. PLoS One, 2017, 12(7): e0181562. |
[1] |
曹风华1,2, 沈花1, 马洁1, 许化溪1, 陈刚3, 李宁3, 王胜军1. 雪菊不同极性萃取物对小鼠脾脏CD4+T细胞体外增殖的影响[J]. 江苏大学学报:医学版, 2019, 29(05): 375-378,385. |
[2] |
李杨1,2, 王颖1,2, 王妍1,2, 施鑫钰1,2, 陈瑾1,2, 钱晖1,2. piR-hsa-1282在脂多糖诱导的293T细胞急性损伤中的作用[J]. 江苏大学学报:医学版, 2019, 29(05): 386-389,393. |
[3] |
邵琦, 李佳丽, 周李宁, 苏兆亮, 许化溪. 人参炔醇重塑巨噬细胞表型调控乳腺癌细胞生物学行为[J]. 江苏大学学报:医学版, 2019, 29(04): 287-292. |
[4] |
宋格, 赵耀, 陆薇, 王胜军. 荷瘤小鼠MDSCs中TRIM25和PTEN的表达[J]. 江苏大学学报:医学版, 2019, 29(04): 333-338. |
[5] |
武丹1, 周玲2, 糜磊1, 周月鹏1, 陈德玉1. TACSTD2调控食管鳞癌细胞对顺铂的敏感性[J]. 江苏大学学报:医学版, 2019, 29(04): 293-298. |
[6] |
施晋升1, 李峰1, 吴思慧2, 俞力超1, 刘黎琼3, 于峰4,5. 携带抗FAP×抗CD3双特异性抗体重组溶瘤痘病毒的构建及其抗癌活性观察[J]. 江苏大学学报:医学版, 2019, 29(04): 327-332. |
[7] |
吴亮1, 陆娟1,2, 王廷廷1, 万晟霞3, 邹治情1, 戴晓玥1,夏雯1, 阴晴4, 陈盛霞1, 许化溪1. 鲍曼不动杆菌荚膜厚度对鼠巨噬细胞炎症复合体活化的影响[J]. 江苏大学学报:医学版, 2019, 29(02): 133-. |
[8] |
史敦绘, 史伟, 娄方明, 锁星星, 李晶, 汤郁. 肿瘤坏死因子-α抑制剂对未使用糖皮质激素类风湿关节炎患者骨代谢水平的影响[J]. 江苏大学学报:医学版, 2019, 29(02): 138-141. |
[9] |
陈香1,2, 许新微3, 张朝阳4, 赵明1,3*. 白藜芦醇治疗炎症性肠病的研究进展[J]. 江苏大学学报:医学版, 2019, 29(02): 179-184. |
[10] |
赵依琳1, 刘月琴2, 周天然2, 周李宁1, 苏兆亮1, 许化溪1. 白藜芦醇通过诱导GMDSCs凋亡和MMDSCs分化延缓Lewis荷瘤小鼠肿瘤生长[J]. 江苏大学学报:医学版, 2019, 29(01): 26-30. |
[11] |
史卫群1, 吕剑平2, 王骞2, 王艳2, 吕进泉2,*. 哮喘患儿血浆TWEAK浓度和外周血单个核细胞中NFκB活性变化及意义[J]. 江苏大学学报:医学版, 2019, 29(01): 82-83. |
[12] |
杭晨, 赵绍杰, 蒋倩颖. 甲氨蝶呤单疗程治疗低危无转移妊娠滋养细胞肿瘤的疗效分析[J]. 江苏大学学报:医学版, 2018, 28(06): 507-. |
[13] |
张秀琳1, 洪煜婧2, 赵枰1,*, 陈相1, 周峰1, 鲁晓燕3. 循环肿瘤细胞对卵巢癌的诊断价值[J]. 江苏大学学报:医学版, 2018, 28(06): 540-. |
[14] |
蒋小芹1,2, 戴桂红2, 朱晓蔚2, 盛海辉3, 张丽华4, 周家华5,*. 成人肾恶性横纹肌样瘤3例临床病理分析[J]. 江苏大学学报:医学版, 2018, 28(06): 546-. |
[15] |
鲁翰林1, 宋盈莹1, 申春苹1, 陈晨1, 刘小草1, 冯超3, 卢斌峰1, 朱一蓓1, 孙中文2, 王雪峰1. 紫杉醇对IL-36γ介导的抗肿瘤作用的影响[J]. 江苏大学学报:医学版, 2018, 28(05): 381-385. |
|
|
|